Skip to main content

Biotechnology Value Fund L P's Form 4 filing

Cullinan Therapeutics, Inc. (CGEM) · filed Apr 5, 2022

Accession no.
0000921895-22-001132
Filed
Apr 5, 2022, 6:45 PM ET
Trade date
Apr 1, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $2.97M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Biotechnology Value Fund L PCIK 0000918923Other: See Explanation of Responses
BVF Partners L PCIK 000105594710% Owner
BVF IncCIK 000105680710% Owner
Biotechnology Value Fund II LPCIK 0001102444Other: See Explanation of Responses
Lampert Mark NCIK 000123384010% Owner
Biotechnology Value Trading Fund OS LPCIK 0001660683Other: See Explanation of Responses
BVF Partners OS Ltd.CIK 0001660684Other: See Explanation of Responses
BVF I GP LLCCIK 0001803805Other: See Explanation of Responses
BVF II GP LLCCIK 0001803806Other: See Explanation of Responses
BVF GP Holdings LLCCIK 000180380910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 1, 2022Common StockPPurchaseAcquired+266,598$10.75+$2,865,901.843,056,616Direct
Apr 1, 2022Common StockPPurchaseAcquired+9,402$10.75+$101,070.562,196,240Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)